Synektik has emerged as a high-quality CEE medtech compounder, combining exclusive robotic surgery distribution, rising recurring revenue, a cleaner post-spin-off profit profile, and meaningful upside from Ukraine and next-generation oncology platforms.
Overview
Synektik is a leading CEE healthcare technology integrator focused on robotic surgery, advanced oncology platforms, imaging IT, services, and Polish radiopharmaceuticals. The Syn2bio spin-off removed volatile R&D costs, creating a cleaner, higher-margin commercial medtech platform. Its moat stems from exclusive global supplier relationships, turnkey clinical support, localized regulatory/service capabilities, and recurring consumables. Customers choose Synektik for full ecosystem delivery, not simple distribution.